Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14.
Lerario AM, Worden FP, Ramm CA, Hsseltine EA, Stadler WM, Else T, Shah MH, Agamah E, Rao K, Hammer GD. The Combination of insulin-like growth factor receptor 1 (IGFR) antibody cixutumumab and mitotane as a first line therapy for patient with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI sponsored trial. Horm Cancer. 2014 Aug; 5 (4) 232-9
Campbell NP, Kunnavakkam R, Leighl N, Vincent MD, Gandara DR, Koczywas M, Gitlitz BJ, Agamah E, Thomas SP, Stadler WM, Vokes EE, Kindler HL Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium. Lung Cancer. 2012 Oct; 78 (1) 76-80
Kindler HL, Wroblewski K, Wallace JA, Hall MJ, Locker G, Nattam S, Agamah E, Stadler WM, Vokes EE. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drug. 2012 Feb; 30 (1): 382-6
Nimeiri, H , Oza A, Morgan R, Huo D, Elit L, Knost J, Wade J, Agamah E, Vokes E, Fleming G A phase II Study of Sorafenib in Advanced Uterine Carcinoma/Carcinosarcoma: A Trial of the Chicago, PMH and California Phase II Consortia. Gynecol Oncol. 2010 Apr; 117 (1) 37-40
The Combination of insulin-like growth factor receptor 1 (IGFR) antibody cixutumumab and mitotane as a first line therapy for patient with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI sponsored trial; Cediranib in patients with malignant mesothelioma; Gemcitabine plus sorafenib in patients with advanced pancreatic cancer; A phase II Study of Sorafenib in Advanced Uterine Carcinoma/Carcinosarcoma; and A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma
